openPR Logo
Press release

Biosimilars Market | Key players in the Biosimilars Market include Pfizer, Sandoz International,Teva Pharmaceuticals, Amgen , Biocon, Dr. Reddy's Laboratories , Celltrion and Samsung Biologics.

05-31-2019 05:10 PM CET | Health & Medicine

Press release from: MarketsandMarkets.com

Biosimilars Market | Key players in the Biosimilars Market

According to a new market research report "Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing Type (In-house, Contract), Disease (Oncology, Autoimmune) - Global Forecast to 2023", published by MarketsandMarkets™, the market is expected to reach USD 23.63 Billion by 2023 from USD 5.95 Billion in 2018, at a CAGR of 31.7%.

Browse 176 market data Tables and 37 Figures spread through 181 Pages and in-depth TOC on "Biosimilars Market"
https://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html?utm_source=OpenPR&utm_medium=Paid

Early buyers will receive 10% customization on this report

The factors expected to drive the growth of this market include the increasing demand for biosimilar drugs due to their cost-effectiveness and the rising incidence of chronic diseases.

Recombinant glycosylated proteins are expected to be accounted for the largest market share in 2018

By product, the biosimilar market is classified into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. Recombinant glycosylated proteins are expected to hold the largest share of the market during the forecast period. The key factors driving the market for glycosylated proteins are the broad therapeutic area of these proteins and presence of biosimilar versions of monoclonal antibodies at lower prices compared to reference products.

Ask for PDF Brochure : https://www.marketsandmarkets.com/pdfdownload.asp?id=40&utm_source=OpenPR&utm_medium=Paid

The in-house manufacturing segment held the largest share of the market in 2017

By type of manufacturing, the market is segmented into in-house manufacturing and contract manufacturing. In-house manufacturing accounted for the largest share of the global Biosimilars Market in 2017. The growing demand for cost-effective biosimilar products owing to the rising incidence of various diseases is driving the growth of the in-house manufacturing segment

Europe accounted for the largest share of the global Biosimilars Market in 2017

Europe accounted for largest share of the global Biosimilars Market in 2017, followed by Asia. Growth in this regional market is expected to be driven by patent expiry of biologic products & the launch of new biosimilars, raising incidence of chronic disorders, and the emergence of new market participants

Request For Sample Report :- https://www.marketsandmarkets.com/requestsampleNew.asp?id=40&utm_source=OpenPR&utm_medium=Paid

Key players in the Biosimilars Market include Pfizer (US), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen (US), Biocon (India), Dr. Reddy's Laboratories (India), Celltrion (South Korea), and Samsung Biologics (South Korea).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: www.marketsandmarkets.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilars Market | Key players in the Biosimilars Market include Pfizer, Sandoz International,Teva Pharmaceuticals, Amgen , Biocon, Dr. Reddy's Laboratories , Celltrion and Samsung Biologics. here

News-ID: 1761267 • Views: 1183

More Releases from MarketsandMarkets.com

Sustainable Growth Opportunities in the Seed Coating Market
The report "Seed Coating Market by Additive (Polymers, Colorants, Pellets, Minerals/Pumice, Active Ingredients), Process (Film Coating, Encrusting, Pelleting), Active Ingredient (Protectants and Phytoactive Promoters), Crop Type, Region - Global Forecast to 2025", is projected to grow at a CAGR of 8.5% from USD 1.8 billion in 2019 to reach a projected value of USD 3.0 billion by 2025. The quality, appearance, and nutritive value of seeds are the key factors
Organic Feed Market Will Hit Big Revenues In Future | Key Players are Cargill, B …
The report "Organic Feed Market by Type (Cereals & Grains, Oilseeds), Form (Pellets, Crumbles, Mashes), Livestock (Poultry, Ruminants, Swine, Aquatic Animals), Additives (Amino Acids, Enzymes, Vitamins, Minerals, Phytogenics), and Region - Global Forecast to 2025" The global organic feed market size is estimated at USD 6.8 billion in 2019 and is projected to reach USD 10.1 billion by 2025, recording a CAGR of 6.8% during the forecast period. The market
Phosphine Fumigation Market to See Major Growth by 2022 |Key Players: Cytec Solv …
The global phosphine fumigation market has grown exponentially in the last few years. The market size is projected to reach USD 684.19 Million by 2022, at a CAGR of around 5.46% from 2017. Factors such as increase in awareness about advanced modes of application of fumigation technology, increasing insect population due to climatic changes, and phasing out of methyl bromide fumigants are expected to drive the market growth. There is
Medicated Feed Additives Market to Witness Unprecedented Growth in Coming Years
The medicated feed additives market is projected to grow at a CAGR of 5.41%, to reach a value of USD 15,320.4 million by 2022 from an estimated USD 11,168.4 million in 2016. Medicated feed additives improve the quality and nutritional content of the feed. These additives help in the growth & development of animals and increase the feed intake. Increase in the awareness of high-quality meat, which is rich in

All 5 Releases


More Releases for Biosimilars

PHASE-XS – Access To Life Changing Biosimilars
Biopharmaceutical is one of the fastest growing industries with addition of numerous biologics that provide novel treatment modalities for life-threatening and rare diseases. Biologics are produced from living organisms through unique manufacturing and purification processes. It includes a wide variety of products such as vaccines, blood, blood components, cells, allergens, genes, tissues, and recombinant proteins that are derived from human, animal or microorganisms by using biotechnological procedures. Some examples for
Global Biosimilars Market Research Report
This report studies the global Biosimilars market status and forecast, categorizes the global Biosimilars market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Pfizer Sandoz International GmbH Teva Pharmaceuticals Industries Amgen Inc Biocon Dr. Reddy’s Laboratories F. Hoffmann-La Roche Celltrion Samsung Bioepis
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American
Humira Biosimilars Clinical Trial Insight
“Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent protection assigned to Humira will expire in 2016 for US and 2018 for European market.
Enbrel Biosimilars Clinical Trial Insight
“Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on